Research ArticleCancer

Optimizing drug combinations against multiple myeloma using a quadratic phenotypic optimization platform (QPOP)

See allHide authors and affiliations

Science Translational Medicine  08 Aug 2018:
Vol. 10, Issue 453, eaan0941
DOI: 10.1126/scitranslmed.aan0941

I’ll have a three-drug combo, please

Combination therapy is a major strategy to circumvent the onset of treatment resistance in cancer patients; knowing which drugs to combine, however, can be difficult. Rashid et al. developed a computational platform to facilitate the discovery and optimization of drug combinations to treat multiple myeloma, a disease that often develops resistance to therapies containing the first-line drug bortezomib. The authors validated the combination treatments and refined the drug dosages in mouse models and ex vivo patient samples. Their platform requires no knowledge of which pathways to target and could more broadly aid drug repurposing efforts.

View Full Text

Stay Connected to Science Translational Medicine